Results 91 to 100 of about 134,759 (289)

Association between glycemic control and antidiabetic drugs in type 2 diabetes mellitus patients with cardiovascular complications

, 2015
Hasniza Zaman Huri,1,2 Doris Yew Hui Ling,1 Wan Azman Wan Ahmad2,3 1Department of Pharmacy, Faculty of Medicine, University of Malaya, Kuala Lumpur, Malaysia; 2Clinical Investigation Centre, University Malaya Medical Centre, Lembah Pantai, Kuala Lumpur,
Huri HZ, Ling DYH, Ahmad WAW
core  

Antimicrobial Peptides and Peptidomimetics in Foods – A Synthetic Foray

ChemFoodChem, EarlyView.
This Review discusses AMPs in foods and their syntheses. It espouses facile methods to make them accessible and suggests their utility in the mitigation and eradication of the burgeoning maladies of antimicrobial and multidrug resistance (AMR and MDR).
Josephat U. Izunobi, Adejoke D. Osinubi, Abosede A. Badeji   +2 more
wiley   +1 more source

Antidiabetic effect of a black mangrove species Aegiceras corniculatum in alloxan-induced diabetic rats

Journal of Advanced Pharmaceutical Technology & Research, 2012
Earlier ethnopharmacological records divulged the traditional usages of mangrove Aegiceras corniculatum (Linn.) Blanco distributed in coastal and estuarine areas of Southeast India. Excluding scientific knowledge of A.
S Gurudeeban, K Satyavani, T Ramanathan, T Balasubramanian   +3 more
doaj   +1 more source

Urogenital Infection Risk Associated With SGLT2 Inhibitors Versus DPP‐4 Inhibitors in Type 2 Diabetes and Chronic Kidney Disease: A Nationwide Target Trial Emulation

Clinical Pharmacology &Therapeutics, EarlyView.
Although sodium‐glucose cotransporter‐2 inhibitors (SGLT2i) are recommended for patients with type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD), concerns regarding urogenital infections persist. Therefore, we evaluated the risk of urinary tract infection (UTI) and genital tract infection (GTI) after SGLT2i initiation in this population ...
Young‐Mi Ah, Junsung Nam, Jung Wook Youn, Yun Mi Yu, Soyoung Kang   +4 more
wiley   +1 more source

Meta‐analysis of sotagliflozin, a dual sodium‐glucose‐cotransporter 1/2 inhibitor, for heart failure in type 2 diabetes

ESC Heart Failure, Volume 12, Issue 2, Page 968-979, April 2025.
Abstract Sodium‐glucose co‐transporters (SGLTs) mediate sodium and glucose transport across cell membranes. SGLT2 inhibitors have a recognized place within heart failure (HF) guidelines. We evaluated the effect of sotagliflozin on HF and cardiovascular outcomes in participants with type 2 diabetes. Scopus, Medline, Embase and Central were searched from
Maria Anna Bantounou, Panagiotis Sardellis, Josip Plascevic, Ribeya Awaes‐Mahmood, Justyna Kaczmarek, Daniel Black Boada, Rosa Thuemmler, Sam Philip   +7 more
wiley   +1 more source

Combining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and disease

, 2008
Kjeld Hermansen, Lene Sundahl Mortensen, Marie-Louise HermansenDepartment of Endocrinology and Metabolism C, Aarhus University Hospital, DK-8000 Aarhus, DenmarkAbstract: Patients with type 2 diabetes mellitus (T2DM) have an increased risk of ...
Marie-Louise Hermansen, Kjeld Hermansen, Lene Sundahl Mortensen   +2 more
core  

Commonalities of platelet dysfunction in heart failure with preserved ejection fraction and underlying comorbidities

ESC Heart Failure, Volume 12, Issue 2, Page 1013-1028, April 2025.
Abstract Heart failure with preserved ejection fraction (HFpEF) is characterized by a lack of a specific targeted treatment and a complex, partially unexplored pathophysiology. Common comorbidities associated with HFpEF are hypertension, atrial fibrillation, obesity and diabetes.
Giorgia D'Italia, Blanche Schroen, Judith M.E.M. Cosemans   +2 more
wiley   +1 more source

Exploring the antioxidant, antidiabetic, and antibacterial potential of postbiotic compounds derived from Lactiplantibacillus plantarum O7S1

Probiotic bacteria are distinguished by their ability to produce various functional postbiotic metabolites. Therefore, this study aimed to explore the in vitro antioxidant, antidiabetic, and antibacterial properties of two postbiotics generated by ...
Houria Ouled-Haddar, Nadia Aliouche, Mohamed Sifour   +2 more
core   +1 more source

Cardiac remodelling in the era of the recommended four pillars heart failure medical therapy

ESC Heart Failure, Volume 12, Issue 2, Page 1029-1044, April 2025.
Abstract Cardiac remodelling is a key determinant of worse cardiovascular outcome in patients with heart failure (HF) and reduced ejection fraction (HFrEF). It affects both the left ventricle (LV) structure and function as well as the left atrium (LA) and the right ventricle (RV).
Giada Colombo, Tor Biering‐Sorensen, Joao P. Ferreira, Carlo Mario Lombardi, Andrea Bonelli, Andrea Garascia, Marco Metra, Riccardo M. Inciardi   +7 more
wiley   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

ESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao, Yang Chen, Zhiyu Ling, Helmut Pürerfellner, Martin Martinek, Michael Derndorfer, Johannes Niel, Ramin Ebrahimi, Matthias Heukäufer, Sarah Janschel, Davide Di Vece, Klaus Empen, Astrid Hummel, Bishwas Chamling, Piotr Futyma, Fahim Ebrahimi, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Alexandra Schratter, Willem‐Jan Acou, Philipp Sommer, Boris Schmidt, Julian K. R. Chun, Christian Meyer, Marcus Dörr, Christian Templin, Shaojie Chen   +27 more
wiley   +1 more source